echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > J HEPATOLOGY: Liver fatty acid binding protein (L-FABP) in urine is a prognostic biomarker of chronic liver failure and mortality in patients with decompensated cirrhosis

    J HEPATOLOGY: Liver fatty acid binding protein (L-FABP) in urine is a prognostic biomarker of chronic liver failure and mortality in patients with decompensated cirrhosis

    • Last Update: 2021-10-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Fatty acid binding protein (FABP) is a group of intracellular chaperone molecules involved in lipid-mediated processes
    .


    FABPs are considered to be key mediators of metabolic and inflammatory pathways


    Fatty acid binding protein (FABP) is a group of intracellular chaperone molecules involved in lipid-mediated processes


     

    The researchers divided the prospective cohort of 444 patients hospitalized with DC into a study cohort (305 patients) and a verification cohort (139 patients)
    .


    L-FABP was measured in urine and plasma samples collected on admission


     

    In univariate analysis, L-FABP in urine rather than plasma was associated with the 3-month survival rate of DC patients
    .


    In multivariate analysis, uL-FABP and the end-stage liver disease sodium model (MELDNa) ​​are the only independent predictors of prognosis


     

    This study confirmed that in terms of mortality and ACLF development, UL-FABP levels are independently related to the 3-month clinical course of DC patients
    .


    If the urine L-FABP and MELDNa scores are combined, it seems to be a better biomarker candidate for DC prognosis prediction


    This study confirmed that in terms of mortality and ACLF development, UL-FABP levels are independently related to the 3-month clinical course of DC patients


     

    Original source:

    Adrià Juanola.


    Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.